Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study

被引:17
|
作者
Blomqvist, C
Hietanen, P
Teerenhovi, L
Rissanen, P
机构
[1] Department of Radiotherapy and Oncology, University of Helsinki, FIN-00290 Helsinki
关键词
breast neoplasm; chemotherapy; metastases;
D O I
10.1016/0959-8049(95)00416-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the study was to define the maximum tolerated dose (MTD) of vinorelbine given as one or two weekly doses in combination with epirubicin 60 mg/m(2) every third week. The MTD was defined as the dose resulting in a WHO grade III or IV leucopenia exceeding 50% of patients. Patients were treated in groups of 10 at escalating doses of vinorelbine. The number of patients at the final dose level was expanded to 20. The dose of epirubicin was kept constant at 60 mg/m(2) every third week. At dose level 1, 15 mg/m(2) vinorelbine was given on day 1 at level 2, 20 mg/m(2) was given on day 1 and at level 3, 20 mg/m(2) was given on days 1 and 8. The MTD was reached at dose level 3. WHO haematological toxicity grade IV occurred in 0, 10 and 45% and grade III at 60, 30 and 30% of patients at dose levels 1, 2 and 3, respectively. Despite the common occurrence of grade IV haematological toxicity, only two serious infections were noted. Non-haematological toxicity of vinorelbine included neurotoxicity, manifesting as muscle weakness, constipation and paresthesias in the majority of patients. Neurotoxicity was usually mild and did not require treatment discontinuation. Phlebitis at the injection site was troublesome in many patients. Alopecia and nausea, probably due to epirubicin, occurred in most patients. The response rates were 22% (95% CI (confidence interval) 3-60%), 40% (12-74%) and 60% (36-81%) at levels 1, 2 and 3, respectively (non-significant).
引用
收藏
页码:2406 / 2408
页数:3
相关论文
共 50 条
  • [1] Epirubicin/vinorelbine as first line therapy in metastatic breast cancer
    Baldini, E
    Tibaldi, C
    Chiavacci, F
    Di Lieto, M
    Fioretto, L
    Giallombardo, A
    Taviani, R
    Ghezzi, P
    Bolognini, A
    Conte, P
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (02) : 129 - 134
  • [2] Epirubicin/vinorelbine as first line therapy in metastatic breast cancer
    Editta Baldini
    Carmelo Tibaldi
    Franco Chiavacci
    Marco Di Lieto
    Luisa Fioretto
    Annalia Giallombardo
    Roberto Taviani
    Paolo Ghezzi
    Anna Bolognini
    Pierfranco Conte
    Breast Cancer Research and Treatment, 1998, 49 : 129 - 134
  • [3] Combination of Docetaxel, Epirubicin and Vinorelbine Administered Every 2 Weeks as First-line Therapy in Patients with Metastatic Breast Cancer: A Dose-finding Study
    Emilio Esteban
    Antonio Modollel
    Luis González de Sande
    Isabel Palacio
    Isabel Muñiz
    Yolanda Fernández
    Norberto Corral
    Joaquin Fra
    Marian Sala
    Jose María Vieitez
    Enrique Estrada
    AJ Lacave
    Breast Cancer Research and Treatment, 2003, 80 : 257 - 265
  • [4] Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer:: a dose-finding study
    Esteban, E
    Modollel, A
    de Sande, LG
    Palacio, I
    Muñiz, I
    Fernández, Y
    Corral, N
    Fra, J
    Sala, M
    Vieitez, JM
    Estrada, E
    Lacave, AJ
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 80 (03) : 257 - 265
  • [5] First-line treatment with epirubicin and vinorelbine in metastatic breast cancer
    Vici, P
    Colucci, G
    Gebbia, V
    Amodio, A
    Giotta, F
    Belli, F
    Conti, F
    Gebbia, N
    Pezzella, G
    Valerio, MR
    Brandi, M
    Pisconti, S
    Durini, E
    Giannarelli, D
    Lopez, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2689 - 2694
  • [6] Epirubicin and vinorelbine versus single agent epirubicin as first line chemotherapy in metastatic breast cancer
    Ejlertsen, B
    Mouridsen, H
    Langkjer, ST
    Andersen, J
    Sjostrom, J
    Kjaer, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S66 - S67
  • [7] Phase II study of gemcitabine (G) and vinorelbine (V) in metastatic breast cancer.
    Donadio, M
    Ritorto, G
    Novarino, A
    Bonazzi, G
    Coccorullo, Z
    Buffoni, L
    Occelli, M
    Bertetto, O
    ANNALS OF ONCOLOGY, 2000, 11 : 31 - 31
  • [8] Phase II study of carboplatin, vinorelbine and capecitabine in patients with metastatic breast cancer.
    Rabinowitz, MJ
    Mangalik, A
    Lee, FC
    Cynthia, C
    Claire, V
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S203 - S203
  • [9] Phase I/II study of carboplatin, vinorelbine and capecitabine in metastatic breast cancer.
    Rabinowitz, MJ
    Mangalik, A
    Lee, FC
    Cathcart, C
    Verschraegen, C
    Rabinowitz, I
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 57S - 57S
  • [10] Improved progression-free survival from the addition of vinorelbine to epirubicin in first line chemotherapy of metastatic breast cancer.
    Ejlertsen, B
    Mouridsen, HT
    Langkjer, ST
    Andersen, J
    Sjostrom, J
    Kjaer, M
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 270 - 270